Literature DB >> 6870919

Mechanisms responsible for the inhibitory effects of benfluorex on hepatic intermediary metabolism.

M J Geelen.   

Abstract

The effects of benfluorex on hepatic intermediary metabolism have been studied using the isolated hepatocyte system. The drug inhibits the synthesis of both glucose and fatty acids by hepatocytes. Evidence is obtained that hepatocytes rapidly split benfluorex into benzoic acid and 1-(3-trifluoromethylphenyl)-2-[N-(2-hydroxyethyl)amino]propane (THEP). Comparison of the effects of the parent compound with the effects of THEP and benzoic acid on gluconeogenesis and on fatty acid synthesis indicates that different metabolites of the drug are responsible for its various actions: THEP inhibits gluconeogenesis, whereas benzoic acid inhibits fatty acid synthesis. The latter pathway appears to be inhibited at two sites: mitochondrial pyruvate uptake is inhibited by benfluorex itself, whereas fatty acid synthase is inhibited by benfluorex-derived benzoic acid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870919     DOI: 10.1016/0006-2952(83)90123-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  The liver metabolite S-422 of the hypolipidaemic drug benfluorex decreases cholesterol esterification in fibroblasts and monocyte-like cells.

Authors:  J C Mazière; C Mazière; M Auclair; L Mora; O Arnaud
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Benfluorex and blood glucose control in non insulin-dependent diabetic patients.

Authors:  P Cavallo-Perin; P Estivi; L Boine; R Galletti; G Pacini; C Cobelli; G Pagano
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

3.  Modulation of glucagon-induced glucose production by dexfenfluramine in rat hepatocytes.

Authors:  B Comte; A Romanelli; S Tchu; G van de Werve
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

Review 4.  Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation.

Authors:  Xiaoli Tang; Zengwu Wang; Shengshou Hu; Bingying Zhou
Journal:  Pharmaceutics       Date:  2022-06-21       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.